Recruiting

Lidocaine

Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Code:

NCT02862769

Conditions

Chronic Pain

Acute Pain

Neuralgia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lidocaine

Saline

Study Details

Brief summary:

The aim of this study is to evaluate the impact of intravenous lidocaine on acute and chronic post surgical pain on patients undergoing video assisted thoracoscopic surgery(VATS). The investigators believe that systemic administration of lidocaine during the perioperative period would be effective in preventing chronic pain post VATS. In addition to chronic pain the investigators believe it will reduce acute postoperative pain as well as each patients total opioid requirement.The investigators believe that this will have a significant impact on the care of patients presenting for VATS.

Conditions

Chronic Pain

Acute Pain

Neuralgia

Study ID

NCT02862769

Start date

Jan 1, 2017

Status verified date

Oct, 2018

Completion date

Dec, 2019

Anticipated

Primary completion date

Dec, 2019

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • VATs for lobectomy
  • Understanding of English (reading, writing and speaking)
  • Written consent for being involved in this study
  • Exclusion Criteria:
  • Chronic pain including fibromyalgia
  • Patients using opioids (more than 80 mg equivalent of oral morphine/day for >60 days)
  • Major depression
  • Received or going to receive chemotherapy or radiotherapy.
  • Pregnant

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Lidocaine infusion

first group (lidocaine group) will include those who receive a intraoperative lidocaine infusion (Induction bolus dose of 1.5 mg/kg body weight followed by a continous lidocaine infusion

placebo comparator: Saline Infusion

The second group will include those who receive a intraoperative placebo i(Induction bolus dose of 1.5 mg/kg body weight of lidocaine followed by a continous saline infusion at the same rate as the lidocaine infusion.

Interventions

Lidocaine

. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.

Saline

The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.

Primary outcome measure

  • Chronic Pain post VATs [ Time Frame: 3 months ]
  • Chronic Pain post VATs [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Qutaiba Tawfic Hamodi

5196466100

Qutaiba Tawfic Hamodi

5196466100qutaiba.Tawfic@lhsc.on.ca

Locations

London Health Sciences Centre

Recruiting

London, Ontario, Canada, N6A 5W9

Contacts

zameer pirani

5198514595piranizameer@gmail.com

More Information

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Last update posted

Oct 24, 2018

Last verified

Oct, 2018

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's on 2018-10-24.